A single-arm feasibility phase II study of EMF (erlotinib + methotrexate + 5-fluorouracil) regimen i...
A single-arm feasibility phase II study of EMF (erlotinib + methotrexate + 5-fluorouracil) regimen in platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
About this item
Full title
Author / Creator
Publisher
Bristol: Cancer Intelligence
Journal title
Language
English
Formats
Publication information
Publisher
Bristol: Cancer Intelligence
Subjects
More information
Scope and Contents
Contents
BackgroundHead and neck squamous cell carcinoma (HNSCC) is a huge burden in India with the majority of patients presenting in advanced unresectable stages. Innovative, low-cost but efficacious regimens that can be easily administered in the outpatient setting are the need of the hour. We envisaged assessing whether a readily available triplet thera...
Alternative Titles
Full title
A single-arm feasibility phase II study of EMF (erlotinib + methotrexate + 5-fluorouracil) regimen in platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2738496780
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2738496780
Other Identifiers
ISSN
1754-6605
E-ISSN
1754-6605
DOI
10.3332/ecancer.2022.1451
